Circulating Muscle Markers for Sarcopenia in Peritoneal Dialysis

Area of Science:

• Nephrology
• Geriatrics
• Biochemistry

Background:

• Sarcopenia, defined as progressive loss of muscle mass and function, is a common complication in patients undergoing peritoneal dialysis (PD).
• Early diagnosis and effective treatment strategies for sarcopenia in PD patients are currently lacking, necessitating further research.
• Understanding the underlying mechanisms and identifying reliable biomarkers are crucial for managing this condition.

Purpose of the Study:

• To review the pathophysiology of sarcopenia in PD patients.
• To examine the potential of various biomarkers for early diagnosis and as therapeutic targets.
• To identify future research directions for sarcopenia management in PD.

Main Methods:

• Literature review of current research on sarcopenia in PD patients.
• Analysis of biomarkers associated with muscle mass and function, including myokines, adipokines, and hormones.
• Synthesis of findings to propose diagnostic and therapeutic strategies.

Main Results:

• Sarcopenia significantly impacts PD patient outcomes.
• Several biomarkers, including myostatin, follistatin, activin A, GDF-15, irisin, adiponectin, leptin, IGF-1, vitamin D, myoglobin, and cortisol, show potential for sarcopenia assessment.
• These markers may aid in early detection and serve as targets for novel therapies.

Conclusions:

• Biomarkers offer a promising avenue for the early diagnosis and treatment of sarcopenia in PD patients.
• Further research is warranted to validate these markers and develop targeted interventions.
• Improved management of sarcopenia can enhance the quality of life and clinical outcomes for PD patients.